5 Key Takeaways

• 1

  Neovascular age-related macular degeneration (nAMD) accounts for most severe vision loss in AMD despite affecting only 10% of patients.

• 2

  Current treatments primarily target VEGF-A, but new agents aim to reduce treatment burden and improve efficacy.

• 3

  EYP-1901 and OTX-TKI are two tyrosine kinase inhibitors progressing to phase 3 trials, showing promising results in reducing treatment burden.

• 4

  Phase 3 trials for EYP-1901 and OTX-TKI will evaluate visual acuity, safety, and need for supplemental aflibercept injections.

• 5

  Other novel therapies in development include various TKIs delivered through different modalities, targeting multiple pathways in nAMD.